Results 71 to 80 of about 268,028 (214)

Akt2 regulates metastatic potential in neuroblastoma. [PDF]

PLoS ONE, 2013
Activation of PI3K/AKT pathway correlates with poor prognosis in patients with neuroblastoma. Our previous studies have demonstrated that PI3K/AKT signaling is critical for the oncogenic transformations induced by gastrin-releasing peptide (GRP) and its ...
Jingbo Qiao, Sora Lee, Pritha Paul, Lan Qiao, Chase J Taylor, Cameron Schlegel, Nadja C Colon, Dai H Chung   +7 more
doaj   +1 more source

Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells [PDF]

, 2015
This research was originally published in Journal of Biological Chemistry. Olesya Chayka, Cosimo Walter D’Acunto, Odette Middleton, Maryam Arab, and Arturo Sala.
Arab, M, Chayka, O, D'Acunto, CW, Middleton, O, Sala, A   +4 more
core   +1 more source

AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells

Acta Pharmaceutica Sinica B, 2023
While neuroblastoma accounts for 15% of childhood tumor-related deaths, treatments against neuroblastoma remain scarce and mainly consist of cytotoxic chemotherapeutic drugs.
Shaowei Bing, Senfeng Xiang, Zhimei Xia, Yilong Wang, Zhonghai Guan, Jinxin Che, Aixiao Xu, Xiaowu Dong, Ji Cao, Bo Yang, Jinhu Wang, Qiaojun He, Meidan Ying   +12 more
doaj  

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Journal of Experimental & Clinical Cancer Research, 2021
Background High-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and the appropriate drugs.
Lijia Pan, Cheng Cheng, Peiwen Duan, Kai Chen, Yeming Wu, Zhixiang Wu   +5 more
doaj   +1 more source

Targeting of the MYCN protein with small molecule c-MYC inhibitors [PDF]

, 2014
This study was funded by grants from the Swedish Research Council and the Swedish Cancer Society. IM and HZ were recipients of graduate student grants from KI (KID), MAH was recipient of a Senior Investigator Award from the Swedish Cancer Society, and ...
Frenzel, Anna, Henriksson, Marie Arsenian, Larsson, Karin, Muller, Inga, Oliynyk, Ganna, Prochownik, Edward V., Westwood, Nicholas J., Zirath, Hanna   +7 more
core   +3 more sources

Epigenetic therapies for neuroblastoma: immunogenicity awakens

Molecular Oncology, 2023
The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex ...
Carlos Jiménez, Lucas Moreno, Miguel F. Segura   +2 more
doaj   +1 more source

A mechanistic classification of clinical phenotypes in neuroblastoma

Science, 2018
A systematic look at a childhood tumor Neuroblastomas—the most common tumor type in infants—develop from fetal nerve cells, and their clinical course is highly variable.
S. Ackermann, Maria Cartolano, B. Hero, A. Welte, Y. Kahlert, Andrea Roderwieser, C. Bartenhagen, E. Walter, Judith Gecht, L. Kerschke, R. Volland, R. Menon, J. Heuckmann, Moritz Gartlgruber, S. Hartlieb, K. Henrich, K. Okonechnikov, J. Altmüller, P. Nürnberg, Steve Lefever, Bram de Wilde, Frederik Sand, F. Ikram, Carolina Rosswog, J. Fischer, J. Theißen, F. Hertwig, A. Singhi, T. Simon, Wenzel Vogel, S. Perner, B. Krug, M. Schmidt, S. Rahmann, V. Achter, Ulrich Lang, C. Vokuhl, M. Ortmann, R. Büttner, A. Eggert, F. Speleman, Roderick J. O’Sullivan, Roman K. Thomas, F. Berthold, J. Vandesompele, A. Schramm, F. Westermann, J. Schulte, M. Peifer, M. Fischer   +49 more
semanticscholar   +1 more source

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study [PDF]

, 2018
Purpose : Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response ...
Amoroso, L, Brock, P, Castel, V, Erminio, G, Garaventa, A, Grp, Siopen, Haupt, R, Ladenstein, R, Laureys, G, Luksch, R, Makin, G, Pasquet, M, Pearson, A. D. J, Thomas, C, Valteau-Couanet, D   +14 more
core   +2 more sources

The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-β1 and focal adhesion kinase activation

Cell Adhesion & Migration, 2021
Neuroblastoma is a highly metastatic tumor that emerges from neural crest cell progenitors. Focal Adhesion Kinase (FAK) is a regulator of cell migration that binds to the receptor Neogenin-1 and is upregulated in neuroblastoma.
Andrea A. Villanueva, Pilar Sanchez-Gomez, Ernesto Muñoz-Palma, Sofía Puvogel, Bárbara S. Casas, Cecilia Arriagada, Isaac Peña-Villalobos, Pablo Lois, Manuel Ramírez Orellana, Fabiana Lubieniecki, Fernando Casco Claro, Iván Gallegos, Javier García-Castro, Vicente A. Torres, Verónica Palma   +14 more
doaj   +1 more source

Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway

Pharmaceuticals, 2023
Background: Chlorogenic acid (CHA) has been shown to have substantial biological activities, including anti-inflammatory, antioxidant, and antitumor effects.
Shen You, Ming-Jin Wang, Zhen-Yan Hou, Wei-Da Wang, Ting-Ting Du, Ni-Na Xue, Ming Ji, Xiao-Guang Chen   +7 more
doaj   +1 more source